Metagenomi Therapeutics Inc (MGX) — 13F Filings Explorer (Q2 2026)

MGX ranks #6568 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

MGX is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

43 institutions disclose a position in MGX, but none treat it as a major bet — even Pura Vida Investments, LLC, its most concentrated holder, allocates just 0.8% of its own portfolio to it.

Fortitude Advisory Group L.L.C. has trimmed its MGX position for two straight quarters, cutting it by $10.3K while still holding $39.5K.

MGX reported a net loss of $93.5M over the trailing twelve months.

• Not yet profitable — net loss of $93.5M over the trailing twelve months
• Revenue declined 50.7% year over year
• Net income declined year over year, from -$87.1M to -$93.5M
• Operating cash flow was negative, using $88.9M in cash
• Current ratio of 7.22x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.39x equity — within a conventional range